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hromosomal abnormalities provide useful diagnostic and
rognostic information, and may also guide therapy in
yeloid malignancies, especially in myelodysplastic syn-
romes (MDS) and acute myeloid leukemia (AML). The revised
nternational prognostic score system for MDS highlights the
mplication of chromosomal abnormalities on the prognosis
f MDS  patients.1 The successes of acute promyelocytic
eukemia patients harboring t(15;17) and treated with all-
rans retinoic acid (ATRA) indicates the value of chromosomal
bnormalities on the diagnosis, prognosis and therapy of
ML.2 Metaphase cytogenetics is a routine test in the man-
gement of myeloid malignancies that allows the detection of
ultiple clones, unbalanced chromosomal defects (deletions
nd gains) and balanced translocations. However, metaphase
ytogenetics is time consuming, it needs cellular proliferation,
ts sensitivity depends on the proportion of clonal cells in the
ample, and its resolution depends on the size of the lesion. At
east 50% of MDS  and AML  patients have normal metaphase
ytogenetic results, and the great clinical diversity among
hese patients has indicated the need for new techniques able
o detect additional molecular alterations that can help in the
iagnosis, prognosis and treatment. Whole genome scanning
echnologies have opened up a new road of investigation for
hromosomal abnormalities in myeloid malignancies and
lso other neoplasms.3 Array-based technologies include
 See paper by Noronha et al. in Rev Bras Hematol Hemoter. 2015;37(1
∗ Corresponding author at: Department of Internal Medicine, Faculdade
USP),  Av. Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil.
E-mail address: ftraina@fmrp.usp.br (F. Traina).
ttp://dx.doi.org/10.1016/j.bjhh.2015.01.007
516-8484/© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia
eserved.comparative genomic hybridization arrays (CGH-A) and single
nucleotide polymorphism arrays (SNP-A).4 More  recently, next
generation sequencing (NGS) technology has also provided
valuable information on chromosomal abnormalities.5
In the last issue of the Revista Brasileira de Hematolo-
gia e Hemoterapia, Noronha et al.6 reported the comparative
results of metaphase cytogenetics and SNP-A in 25 Brazil-
ian patients with diagnoses of AML or MDS; chromosomal
abnormalities were detected in 40% and 68% of patients by
metaphase cytogenetics and SNP-A technology, respectively.
As demonstrated by Noronha et al.,6 SNP-A technology does
not depend on the presence of dividing cells, has the abil-
ity to detect copy number variations (deletions and gains)
with a higher resolution than conventional cytogenetics, and
to detect copy number neutral loss of heterozygosity (CN-
LOH), also named somatic uniparental disomy (UPD). However,
SNP-A does not detect balanced translocations, does not dis-
tinguish individual clones; and does not detect small clones.4
As such, SNP-A does not replace metaphase cytogenetics, and
combined methods will probably be necessary to improve the
clinical care of patients with myeloid malignancies. Another
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parison of SNP-A results obtained from the germ-line DNA
sample (buccal cells) and the tumor sample (bone marrow
mononuclear cells). This approach is recommended to exclude
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normal copy number variations from somatic/acquired gains,
deletions or UPD. Normal copy number variations, in general,
are smaller than 1 Mb  and may have characteristic locations,7
as indicated in public databases.
Two other important contributions of SNP-A technology to
myeloid malignancies need to be highlighted. SNP-A was ﬁrst
used as an investigative tool, which allowed the identiﬁca-
tion of various common deleted regions and the discovery of
several important gene mutations exempliﬁed by CBL, TET2,
and EZH2 mutations.8 New lesions detected by SNP-A may
have prognostic implications in MDS9 and AML10; however,
the validation of this ﬁnding in different cohorts of patients
is necessary. The high cost of SNP-A limits its use in the rou-
tine clinical setting. The work by Noronha et al.6 represents
an important step in establishing the use of SNP-A in Brazil-
ian patients with myeloid malignancies in a research scenario,
which may be important to better deﬁne the somatic chromo-
somal abnormalities in our population and may be a valuable
tool to investigate molecular mechanisms involved in Brazil-
ian cases of familial myeloid malignancies.
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